Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant

Trial Profile

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Sofosbuvir/velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
    • 04 Oct 2017 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
    • 04 Oct 2017 Planned initiation date changed from 15 Sep 2017 to 15 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top